BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $180
AbbVie, Inc. +1.19% Pre
AbbVie, Inc. ABBV | 188.76 188.76 | +1.19% 0.00% Pre |
BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:
ABBV) with a Outperform and lowers the price target from $195 to $180.